ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1452	National Cancer Institute	Html	en	Cigarette Smoking: Health Risks and How to Quit (PDQ®)–Health Professional Version	Expert-reviewed information summary about research and guidelines focused on the prevention and cessation of cigarette smoking.	smoking cessation strategy 0.633721 smoking cessation rates 0.605741 quit attempt 0.552085 effective smoking cessation 0.580922 gradual cessation group 0.483049 abrupt cessation 0.562882 prolonged validated smoking 0.480554 lung cancer 0.658405 tobacco cessation 0.463262 smoking cessation pharmacotherapies 0.597527 abrupt smoking cessation 0.601297 pipe tobacco smoking 0.505275 current smoking 0.475722 gradual cessation arm 0.465437 nicotine replacement therapy 0.54532 randomized trial 0.492165 Smoking cessation counseling 0.609156 receptor partial agonist 0.460896 area-level smoking prevalence 0.513667 smoking reduction 0.49426 smoking behavior 0.469981 smoking cessation treatment 0.588411 smoking prevalence data 0.513642 tobacco products 0.485537	abrupt cessation arm 0.472163 smoking cessation 0.926558 vs abrupt cessation 0.475821 adult cigarette smoking 0.474818 gradual cessation method 0.466403 cigarette smoking cessation 0.573293 cigarette smoking 0.62168 smoking cessation pharmacotherapy 0.595082 varenicline 0.542592 tobacco smoking 0.505702 smoking cessation rate. 0.602815 gradual cessation 0.501212 abrupt cessation group 0.489713 nicotinic acetylcholine receptor 0.464069 self-reported smoking abstinence 0.502629 smoking abstinence 0.574891 cigarette smoking prevalence 0.566333 randomized controlled trial 0.482431 6-month cessation rates 0.474432 nicotine patch 0.531368 smoking cessation intervention 0.590903 usual smoking patterns 0.480697 lung cancer mortality 0.510576 varenicline group 0.534998	CLICK HERE
1682	National Cancer Institute	Html	en	Family Caregivers in Cancer: Roles and Challenges (PDQ®)–Health Professional Version	Expert-reviewed information summary about the challenges faced by family caregivers of cancer patients. This summary focuses on typical caregiver roles and concerns, and helpful interventions for caregivers.	caregiver strain 0.637562 caregiver self-efficacy 0.583778 caregiver involvement 0.610915 cancer care facility 0.578352 palliative care consultation 0.608288 caregiver knowledge 0.586068 Hispanic caregivers 0.676204 caregiver 0.821035 Caregiver quality 0.603509 white caregivers 0.639176 health care providers 0.59721 specialist-level palliative care 0.56948 caregiver well-being 0.592799 patient symptom care 0.583377 culturally competent care 0.564531 patients 0.715455 cancer patients 0.703941 Asian American caregivers 0.689382 caregiver emotional health 0.625075 secondary informal caregivers 0.653486 caregiver burden 0.63516 caregiver’s information 0.595277 symptom management 0.696609 orient caregivers 0.633121 primary caregiver 0.613245	caregiver portion 0.581896 African American caregivers 0.664952 caregiver needs 0.592313 end-of-life care 0.586635 family caregivers 0.726566 study 0.578902 problem-solving intervention 0.564815 bereaved caregivers 0.642182 palliative care 0.6279 tailored caregiver interventions. 0.613747 African American patients 0.595756 caregivers 0.977146 terminally ill patients 0.564522 studies 0.568233 empowers caregivers 0.628512 caregiver roles 0.620453 minority caregivers 0.663649 emotional support 0.572233 home care workers 0.567134 Caregivers report 0.630818 Caregiver assessment 0.592589 family caregiver 0.60516 cancer patient 0.576832 difficult caregiver responsibilities 0.601191	CLICK HERE
1790	National Cancer Institute	Html	es	Trastornos del sueño (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de las causas y manejo de los trastornos del sueño en las personas con cáncer.	menudo causa problemas 0.738807 TCC ayuda 0.533662 pequeño número 0.542064 siguientes aspectos 0.690699 siguientes elementos 0.547894 leucemia linfocítica aguda 0.539982 sudores nocturnos 0.6269 siguientes cambios 0.544948 menor número 0.522208 Frecuencia respiratoria 0.534403 fase monr 0.549571 salud afectarán 0.52618 National Cancer Institute 0.522679	sueño mejora 0.68532 siguientes riesgos 0.520223 sueño mor 0.930755 Instituto Nacional 0.543079 siguientes problemas 0.588617 siguientes funciones 0.571878 Physician Data Query 0.591028 fase mor 0.552867 PDQ Trastornos 0.547079 auto hipnosis 0.530427 numerosas razones 0.546303 solo relajarme 0.534672	CLICK HERE
2079	National Cancer Institute	Html	es	BRCA1 y BRCA2: Riesgo de cáncer y pruebas genéticas	Hoja informativa acerca de los genes BRCA1 y BRCA2, de qué hacer si una persona tiene resultados positivos para una de estas alteraciones, y de las consecuencias de las pruebas genéticas.	with inherited mutations 0.40971 Fanconi anemia 0.442696 general padecerán cáncer 0.476912 Lubinski J 0.414965 Cancer Statistics Review 0.41308 brca1 or brca2 0.539593 largo plazo 0.414755 American Cancer Society 0.413258 posibles perjuicios 0.41059 Biallelic mutations 0.410182 National Comprehensive Cancer 0.413868 Breast Cancer Research 0.418728 with brca1 or 0.423664 Múltiples cánceres 0.410805 mutaciones específicas dañinas 0.471623 brca2 mutations 0.589927 among male brca1 0.421616 or genetic predisposition 0.416124 BRCA2 padecerán 0.44228 gen palb2 0.413362 BRCA1 mutation carriers 0.444383 Estados Unidos 0.427518 padecerán cáncer 0.566332 mutaciones dañinas 0.851633 PubMed Abstract 0.989166	mutation carriers identified 0.410419 seno masculino 0.429589 Clinical Oncology 0.441136 BRCA2 carriers 0.419799 risks among brca1 0.420776 BRCA2 mutation carriers 0.508942 BRCA2 mutations detected 0.422577 contralateral breast 0.413156 National Cancer Institute 0.442375 Cancer Research 0.430441 Breast Cancer Prevention 0.417323 antecedentes familiares 0.783866 or brca2 mutations 0.503006 mutation carriers with 0.423928 breast cancer 0.531052 clinical breast examination 0.410267 mujeres padecerán 0.409393 mujeres portadoras 0.421608 gen brca1 0.536899 asesoría genética 0.435987 cancer risk 0.445775 New England Journal 0.415366 bilateral profiláctica 0.437879 BRCA2 mutations account 0.4223	CLICK HERE
2105	National Cancer Institute	Html	es	Exámenes de detección del cáncer de endometrio (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de endometrio.	Surgical Adjuvant Breast 0.318516 Obstet Gynecol 0.462808 endometrial neoplasia 0.330318 endometrial carcinoma 0.35462 mujeres asintomáticas conducirán 0.327753 endometrial biopsy 0.375747 Society Cancer Detection 0.324775 Sin embargo 0.322994 American Cancer Society 0.532275 Barakat RR 0.322448 postmenopausal estrogen 0.311047 Hereditary nonpolyposis colon 0.316803 Cancer Society Guidelines 0.326353 mutation analysis 0.309345 CA Cancer 0.344524 ecografía transvaginal 0.32543 Instituto Nacional 0.316776 PDQ Exámenes 0.310268 Natl Cancer Inst 0.409601 Vasen HF 0.314679 Bowel Project P-1 0.314149 Survival analysis 0.309166 endometrial thickness 0.328405 Gynecol Oncol 0.319248 patients with 0.312917	endometrial cancer 0.986652 Endometrial morphology 0.328059 Genetics Studies Consortium 0.313592 Cancer Facts 0.328027 Cancer risk 0.385512 with endometrial biopsy 0.334209 mutation carriers 0.308983 Cancer Survival Study 0.330775 hereditary nonpolyposis 0.373835 National Cancer Institute 0.323419 endometrial biopsy specimens 0.329768 replacement therapy 0.315579 postmenopausal women 0.352328 Clin Oncol 0.321066 Gynaecol Obstet 0.310774 PDQ Genetics 0.309874 mujeres portadoras 0.322212 adjuvant breast 0.320298 ecografía endovaginal 0.333573 endometrial abnormalities 0.37706 National Surgical Adjuvant 0.314342 Ultrasound Obstet Gynecol 0.310185 mujeres morirán 0.321645 Mecklin JP 0.317214	CLICK HERE
3523	National Cancer Institute	Html	es	Estudio NCI-MATCH (Análisis Molecular para Selección de Tratamientos)	Información sobre el estudio del NCI: Análisis Molecular para Selección de Tratamientos (NCI-MATCH), en el cual los investigadores examinarán tejidos de tumor de pacientes con tumores sólidos y linfomas avanzados que han dejado de responder al tratamiento.	Tumor Profiling 0.554625 estudio match 0.941659 Investigación Oncológica 0.6022 MD Anderson 0.61416 Memorial Sloan-Kettering Cancer 0.578519 Clinical Trials 0.539697 posibles participantes 0.607033 C2 MET 0.546519 Life Sciences 0.627896 laboratorios foundation medicine 0.56991 Foundation Medicine 0.623082 Memorial Sloan-Kettering identificarán 0.577406 estudio comet 0.807536 Grupo Cambio 0.537516 met amp crizotinib 0.576245	como los costos 0.539059 seguro médico 0.533808 Cancer Center 0.605302 MD Anderson Cancer 0.572606 tratamiento inscribirán 0.618222 sk crizotinib 0.541473 cabo estudios 0.534561 Caris Life Sciences 0.579205 Investigación Oncológica ECOG-ACRIN 0.571301 Memorial Sloan-Kettering 0.625566 egfr mut afatinib 0.573282 NRG Oncology Group 0.568484 Iniciativa de Medicina 0.538366 Life Sciences identificarán 0.57351	CLICK HERE
15802	National Cancer Institute	Html	null	About the Blue Ribbon Panel	Information about the Cancer Moonshot Blue Ribbon Panel of experts. The panel was established to ensure the Cancer Moonshot's goals and approaches are grounded in the best science.			CLICK HERE
16716	National Cancer Institute	Html	en	NCI Cancer Moonshot℠ Public Access and Data Sharing Policy	NCI has established a data sharing policy that supports open, public access to all research and data for projects funded as part of the Cancer Moonshot. Find details on the policy.	Underlying Primary Data 0.835591 National Cancer Advisory 0.204571 Creative Commons 0.266314 Cancer Moonshotâ„  0.229846 Moonshot Research Project 0.326921 public domain tool 0.238273 extramural Cancer Moonshot 0.217832 Cancer Moonshot beginning 0.210573 cancer research 0.226051 Data Sharing Repositories 0.219342 underlying data 0.223365 NIH Sharing Policies 0.206938 Genomic Data Sharing 0.238331 Moonshot Research Projects 0.712789 Cancer Moonshotâ„  Research 0.221203 NIH Data Sharing 0.283755 National Cancer Institute 0.205263 Cancer Moonshot Projects 0.211704 public access 0.827988	Blue Ribbon Panel 0.23172 Cancer Moonshot Research 0.963477 independent data access 0.222133 data sharing policies 0.240205 Public Access Policy. 0.214656 nih public access 0.329101 Genomic Data Commons 0.208284 Enhanced Data Sharing 0.250631 Public Access Policy 0.237717 NCI-Supported Cancer Moonshot 0.379658 appropriate Public Access 0.254192 cancer research projects 0.217712 NCI researchers 0.205129 NCI intramural Cancer 0.231006 Data Sharing Policy 0.330676 Rule.7 Underlying Primary 0.217644 Data Sharing Plan 0.965755 intramural Cancer Moonshot 0.258314 Cancer Moonshot Public 0.244424	CLICK HERE
16848	National Cancer Institute	Html	en	Treatment and Therapy	Nanotechnology offers the means to target therapies directly and selectively to cancerous cells and neoplasms. With these tools, clinicians can safely and effectively deliver chemotherapy, radiotherapy, and the next generation of immuno- and gene therapies to the tumor. Futhermore, surgical resection of tumors can be guided and enhanced by way of nanotechnology tools. Find out how nanotechnology will offer the next generation of our therapeutic arsenal to the patient.	cancer treatment 0.854097 tumor type 0.82492 tumor tissues 0.889211 Cancer therapies 0.820703 large surface area 0.827043 nanoparticles 0.943843 superficial tumor 0.871555 nanotechnology cancer therapy 0.925806 multiple myeloma patients 0.821624 RNA-based genetic therapeutics 0.82576 cancer therapeutics 0.879587 vivo RNA nanoparticle 0.839578 nucleic acids 0.851966 electromagnetic radiation modalities 0.829021 cancer immunotherapy deepens 0.869884 artificial antigen 0.824529 Host Cell Response 0.906892 radiation therapy 0.999924 Standalone nanoparticle vaccines 0.835115 multiple dendritic cell 0.822099 conventional radiation therapy 0.856977 tumor vasculature permeability 0.888964 Cancer Nanotechnology Excellence 0.870289 tumor mass 0.82439	photodynamic therapy 0.836532 Cancer Nanotechnology awardees 0.958295 cancer cells 0.999243 external radiation sources 0.839028 small molecule compounds 0.820814 Cancer Therapy Center 0.956254 form Cherenkov radiation 0.829553 tumor accumulation 0.82268 atomic number nanoparticles 0.859022 Biology Cancer Center 0.860679 current radiotherapy dosage 0.82716 delivery 0.878526 combination drug delivery 0.856304 current treatment modalities 0.839227 superficial tumor sites 0.867918 innovative nanoparticle packages 0.854373 Gene silencing therapeutics 0.826818 tissue tumor targets 0.869042 electromagnetic radiation 0.829381 nanomaterial-based delivery platforms 0.862296 external electromagnetic radiation 0.823812 tumor 0.913691 tumor microenvironment 0.865684 deep tissue tumors 0.824773	CLICK HERE
17234	National Cancer Institute	Html	en	Adding Immune-based Treatments to Standard Glioblastoma Therapy	This clinical trial is testing standard therapy (surgery, radiation and temozolomide) plus immunotherapy with pembrolizumab with or without a cancer treatment vaccine for patients with newly diagnosed glioblastoma, a common and deadly type of brain tumor.	immune checkpoint inhibitor 0.991382 Dr. Gilbert 0.728039 tumor tissue 0.405841 trial contact information 0.29929 experimental vaccine 0.247456 1-year overall survival 0.300393 NCI’s Cancer 0.233291 Treating Patients 0.208707 little tumor tissue 0.376059 standard therapy plus 0.329661 immune response 0.550076 NCI Clinical Trials 0.330246 chemotherapy drug temozolomide 0.399109 cancer treatment vaccine 0.66133 primary brain tumor 0.428278 Cancer Research 0.215559 clinical trials 0.480839	slow tumor growth 0.416918 partially randomized phase 0.30891 patients 0.251176 Mark R. Gilbert 0.399405 tumor-specific vaccine 0.249165 experimental cancer treatment 0.582716 immune checkpoint inhibitors 0.542772 microscopic tumor 0.266367 newly diagnosed glioblastoma 0.842005 Current standard therapy 0.36143 placebo vaccine 0.253985 immunotherapy drug pembrolizumab 0.351275 median survival time 0.347591 protocol summary 0.359999 radiation therapy 0.342013 standard therapy 0.747186	CLICK HERE